Q4 EPS Forecast for Soleno Therapeutics Lifted by Analyst

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Stock analysts at Lifesci Capital lifted their Q4 2025 EPS estimates for Soleno Therapeutics in a report released on Monday, January 12th. Lifesci Capital analyst K. Dellorusso now expects that the company will post earnings per share of $0.59 for the quarter, up from their previous forecast of $0.46. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q1 2026 earnings at $0.58 EPS, Q2 2026 earnings at $0.71 EPS, Q3 2026 earnings at $0.74 EPS, Q4 2026 earnings at $0.91 EPS and FY2026 earnings at $3.42 EPS.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.39. The business had revenue of $66.02 million for the quarter, compared to analysts’ expectations of $47.46 million.

A number of other research firms have also commented on SLNO. Zacks Research raised Soleno Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Wednesday, October 8th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $106.00 target price (down previously from $123.00) on shares of Soleno Therapeutics in a report on Wednesday, November 5th. Wolfe Research set a $60.00 price target on Soleno Therapeutics in a research report on Monday. Finally, The Goldman Sachs Group set a $125.00 price objective on shares of Soleno Therapeutics and gave the company a “buy” rating in a research report on Tuesday, October 7th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Soleno Therapeutics currently has an average rating of “Buy” and an average target price of $109.23.

Soleno Therapeutics Trading Up 2.3%

Shares of SLNO stock opened at $42.46 on Thursday. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -23.08 and a beta of -3.12. The company’s fifty day simple moving average is $47.72 and its two-hundred day simple moving average is $63.17. Soleno Therapeutics has a 1 year low of $39.43 and a 1 year high of $90.32. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.08 and a quick ratio of 15.88.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of SLNO. Vanguard Group Inc. increased its position in shares of Soleno Therapeutics by 12.8% in the third quarter. Vanguard Group Inc. now owns 2,807,149 shares of the company’s stock worth $189,763,000 after purchasing an additional 319,317 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in shares of Soleno Therapeutics by 25.7% in the 3rd quarter. Avoro Capital Advisors LLC now owns 2,577,777 shares of the company’s stock worth $174,258,000 after buying an additional 527,777 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Soleno Therapeutics by 272.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company’s stock valued at $156,298,000 after buying an additional 1,691,057 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Soleno Therapeutics by 132.3% during the 3rd quarter. Invesco Ltd. now owns 1,500,525 shares of the company’s stock worth $101,435,000 after acquiring an additional 854,551 shares during the last quarter. Finally, Westfield Capital Management Co. LP lifted its holdings in shares of Soleno Therapeutics by 18.0% during the 2nd quarter. Westfield Capital Management Co. LP now owns 1,429,756 shares of the company’s stock worth $119,785,000 after acquiring an additional 218,511 shares during the last quarter. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.